8dmi
From Proteopedia
(Difference between revisions)
| Line 3: | Line 3: | ||
<StructureSection load='8dmi' size='340' side='right'caption='[[8dmi]], [[Resolution|resolution]] 3.26Å' scene=''> | <StructureSection load='8dmi' size='340' side='right'caption='[[8dmi]], [[Resolution|resolution]] 3.26Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[8dmi]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[8dmi]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Mammarenavirus_choriomeningitidis Mammarenavirus choriomeningitidis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=8DMI OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=8DMI FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.26Å</td></tr> |
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8dmi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8dmi OCA], [https://pdbe.org/8dmi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8dmi RCSB], [https://www.ebi.ac.uk/pdbsum/8dmi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8dmi ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=8dmi FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=8dmi OCA], [https://pdbe.org/8dmi PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=8dmi RCSB], [https://www.ebi.ac.uk/pdbsum/8dmi PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=8dmi ProSAT]</span></td></tr> | ||
</table> | </table> | ||
| Line 13: | Line 14: | ||
The mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a globally distributed zoonotic pathogen that can be lethal in immunocompromised patients and can cause severe birth defects if acquired during pregnancy. The structure of the trimeric surface glycoprotein, essential for entry, vaccine design, and antibody neutralization, remains unknown. Here, we present the cryoelectron microscopy (cryo-EM) structure of the LCMV surface glycoprotein (GP) in its trimeric pre-fusion assembly both alone and in complex with a rationally engineered monoclonal neutralizing antibody termed 18.5C-M28 (M28). Additionally, we show that passive administration of M28, either as a prophylactic or therapeutic, protects mice from LCMV clone 13 (LCMV(cl13)) challenge. Our study illuminates not only the overall structural organization of LCMV GP and the mechanism for its inhibition by M28 but also presents a promising therapeutic candidate to prevent severe or fatal disease in individuals who are at risk of infection by a virus that poses a threat worldwide. | The mammarenavirus lymphocytic choriomeningitis virus (LCMV) is a globally distributed zoonotic pathogen that can be lethal in immunocompromised patients and can cause severe birth defects if acquired during pregnancy. The structure of the trimeric surface glycoprotein, essential for entry, vaccine design, and antibody neutralization, remains unknown. Here, we present the cryoelectron microscopy (cryo-EM) structure of the LCMV surface glycoprotein (GP) in its trimeric pre-fusion assembly both alone and in complex with a rationally engineered monoclonal neutralizing antibody termed 18.5C-M28 (M28). Additionally, we show that passive administration of M28, either as a prophylactic or therapeutic, protects mice from LCMV clone 13 (LCMV(cl13)) challenge. Our study illuminates not only the overall structural organization of LCMV GP and the mechanism for its inhibition by M28 but also presents a promising therapeutic candidate to prevent severe or fatal disease in individuals who are at risk of infection by a virus that poses a threat worldwide. | ||
| - | Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus.,Moon-Walker A, Zhang Z, Zyla DS, Buck TK, Li H, Diaz Avalos R, Schendel SL, Hastie KM, Crotty S, Saphire EO Cell Chem Biol. 2023 | + | Structural basis for antibody-mediated neutralization of lymphocytic choriomeningitis virus.,Moon-Walker A, Zhang Z, Zyla DS, Buck TK, Li H, Diaz Avalos R, Schendel SL, Hastie KM, Crotty S, Saphire EO Cell Chem Biol. 2023 Apr 20;30(4):403-411.e4. doi: , 10.1016/j.chembiol.2023.03.005. Epub 2023 Mar 28. PMID:36990092<ref>PMID:36990092</ref> |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| Line 23: | Line 24: | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | [[Category: Large Structures]] | ||
| - | [[Category: | + | [[Category: Mammarenavirus choriomeningitidis]] |
[[Category: Hastie KM]] | [[Category: Hastie KM]] | ||
[[Category: Moon-Walker A]] | [[Category: Moon-Walker A]] | ||
[[Category: Saphire EO]] | [[Category: Saphire EO]] | ||
[[Category: Zyla DS]] | [[Category: Zyla DS]] | ||
Current revision
Lymphocytic choriomeningitis virus glycoprotein
| |||||||||||
